Concerta

Concerta Adverse Reactions

methylphenidate

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Full Prescribing Info
Adverse Reactions
Clinical Trial Data: Double-Blind Data: Adverse Drug Reactions Reported at ≥1% Frequency: Adverse drug reactions (ADRs) in either the pediatric or adult double-blind adverse drug reaction tables may be relevant for both patient populations.
Pediatric Patients: The safety of Concerta was evaluated in 639 pediatric patients (children and adolescents) with ADHD who participated in 4 placebo-controlled, double-blind clinical trials. The information presented in this section was derived from pooled data.
Adverse drug reactions reported by ≥1% of Concerta-treated subjects in these trials are shown in Table 3.

Click on icon to see table/diagram/image

The majority of ADRs were mild to moderate in severity.
Adult Patients: The safety of Concerta was evaluated in 627 adult patients with ADHD who participated in 2 placebo-controlled, double-blind clinical trials. The information presented in this section was derived from pooled data.
Adverse drug reactions reported by ≥1% of Concerta-treated patients in these trials are shown in Table 4.

Click on icon to see table/diagram/image

The majority of ADRs were mild to moderate in severity.
Open-Label Data: Adverse Drug Reactions Reported at ≥1% Frequency: The safety of Concerta was evaluated in 3590 pediatric and adult subjects with ADHD who participated in 11 open-label clinical trials. The information presented in this section was derived from pooled data.
Adverse drug reactions reported by ≥1% of Concerta-treated subjects in these trials and not listed in Tables 3 and 4 are shown in Table 5.

Click on icon to see table/diagram/image

The majority of ADRs were mild to moderate in severity.
Double-Blind and Open-Label Data: Adverse Drug Reactions Reported at <1% Frequency: Additional ADRs that occurred in <1% of Concerta-treated subjects in the double-blind and open-label clinical datasets are as follows: Blood and Lymphatic System Disorders: Leukopenia.
Psychiatric Disorders: Anger, hypervigilance, altered mood, mood swings, sleep disorder, tearfulness, tic.
Nervous System Disorders: Lethargy, somnolence, psychomotor hyperactivity.
Eye Disorders: Dry eyes.
Vascular Disorders: Hypertension.
Respiratory, Thoracic and Mediastinal Disorders: Dyspnea.
Skin and Subcutaneous Tissue Disorders: Macular rash.
Reproductive System and Breast Disorders: Erectile dysfunction.
Investigations: Cardiac murmur.
The majority of ADRs were mild to moderate in severity.
Post-Marketing Data: ADRs identified during post-marketing experience with Concerta are included in the following texts. The frequencies are provided according to the following convention: Very common: ≥1/10; common ≥1/100 to <1/10; uncommon: ≥1/1000 to <1/100; rare: ≥1/10,000 to <1/1000; very rare <1/10,000, including isolated reports.
The following ADRs are presented by frequency category based on incidence in clinical trials, when known: Blood and Lymphatic System Disorders: Not Known: Pancytopenia, thrombocytopenia, thrombocytopenic purpura.
Immune System Disorders: Uncommon: Hypersensitivity reactions eg, angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticarias, pruritus NEC, rashes, eruptions and exanthemas NEC.
Psychiatric Disorders: Rare: Disorientation, auditory and visual hallucinations, mania. Not Known: Hallucinations.
Nervous System Disorders: Uncommon: Dyskinesia. Not Known: Convulsions, grand mal convulsions.
Eye Disorders: Rare: Diplopia, mydriasis, visual disturbance.
Cardiac Disorders: Rare: Angina pectoris, extrasystoles, ventricular extrasystoles. Not Known: Bradycardia, supraventricular tachycardia.
Vascular Disorders: Not Known: Raynaud's phenomenon.
Skin and Subcutaneous Tissue Disorders: Uncommon: Alopecia, erythema.
Musculoskeletal, Connective Tissue and Bone Disorders: Uncommon: Myalgia, arthralgia, muscle twitching.
General Disorders and Administration Site Conditions: Uncommon: Chest pain and discomfort. Not Known: Decreased drug effect, hyperpyrexia, decreased therapeutic response.
Investigations: Uncommon: Increased hepatic enzyme. Rare: Increased blood bilirubin. Not Known: Increased blood alkaline phosphatase, decreased platelet count, abnormal white blood cell count.
Note: The frequency category “not known” is used for ADRs for which no valid estimate of the incidence rate can be derived from clinical trials.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in